Tamtam Try Tamtam free
HARTMANN GROUP logo

HARTMANN GROUP account plan

Healthcare innovation and improvement

At a glance

HARTMANN GROUP is a German maker of medical and care products (MoliCare, Zetuvit, Sterillium) with FY2025 revenue of EUR 2,449.6 million.

The HARTMANN GROUP, headed by PAUL HARTMANN AG in Heidenheim, Germany (founded 1818), supplies incontinence, wound care and infection prevention products, plus personal care through Kneipp, to hospitals, care homes, pharmacies, the medical-supply trade and home care. It has its own companies in 36 countries and sells in more than 130, with Germany at 31.7% of revenue and EMEA ex-Germany at 58.6%. In FY2025 revenue was EUR 2,449.6 million (+2.2% organic), adjusted EBITDA EUR 276.9 million at an 11.3% margin and group net income EUR 65.8 million. It employed 10,066 people at the end of 2025. Its shares trade on the Open Market of the Frankfurt exchange.

Business units

Strategic priorities

PLUS2030 strategy
Grow faster than competitors in market share and margin, aiming for a number 1 or 2 position in Europe in each segment served, with more focus on sales efficiency, new products and structural cost improvements.
Cost and efficiency programme
The 2019-2025 Transformation Program contributed about EUR 270 million cumulatively, and about EUR 50 million more is expected in 2026; PLUS2030 adds gains from digitalisation, standardisation and targeted use of artificial intelligence.
Advanced wound care in the US
Grow advanced wound care with silicone as the key technology and expand sales in the US outpatient market; Americas revenue grew 12.5% organically in H1 2026.
Innovation with measurable benefits
Every new product must show measurable clinical, operational, patient, economic and, where possible, sustainability benefits; R&D spending was EUR 97.4 million in 2025.
2026 guidance
Moderate organic revenue growth and adjusted EBITDA of EUR 270 to 310 million, confirmed in August 2026.

Latest results

In H1 2026 revenue rose to EUR 1,252.0 million from EUR 1,214.0 million, an organic increase of 3.3% with all core segments contributing. Adjusted EBITDA rose by EUR 25.9 million to EUR 151.7 million, lifting the margin to 12.1% from 10.4%, and group net income reached EUR 57.6 million against EUR 18.1 million. Operating cash flow was EUR 126.2 million against EUR 15.7 million. HARTMANN confirmed its 2026 guidance but expects higher material, energy and freight costs from the Iran war to weigh more on the second half, and negative effects in 2027 from German statutory health insurance and long-term care reforms.

Investments and deals

Production capex
Capex of EUR 160.4 million in 2025, 56.0% of it in Germany, including production lines in Germany, France and Spain and high-speed wound dressing lines in France and Poland.
SAP S/4HANA rollout
The global migration went live in May 2025 across 28 countries, 17 production sites and 104 warehouses, used by more than 5,500 employees.
Footprint changes
Wound care production is being relocated to Poland, a Czech plant is closing with 200 people affected, and further investment is planned at the Herbrechtingen plant and warehouse.
Pierre Cattier divestment
Kneipp's unprofitable French natural-cosmetics subsidiary was sold in 2025, with a EUR 18.7 million adjustment.

Challenges and risks

Reimbursement cuts
Wound care reimbursement restrictions in France since April 2025, unclear German reimbursement of antimicrobial dressings, and the German hospital, statutory health insurance and long-term care reforms.
Cost inflation
High material, energy and freight costs, raised further by the Iran war in 2026, can only partly be passed on through prices.
Price pressure and Asian competition
Strong competition from Southeast Asia in traditional wound care and high price pressure in examination gloves; hospitals and care homes award contracts to the cheapest bidder.
Regulatory burden
EU MDR recertification of thousands of products and up to 150 mandatory EUDAMED fields per product slow innovation, according to the CEO.
Tariffs and compliance
15% US tariffs on EU medical products, and antitrust damage claims against two Spanish subsidiaries with an EUR 11.8 million provision.

What leadership says

“two things that actually contradict each other: cut costs and invest in innovation”

Britta Fünfstück, CEO · Schwäbische Post interview, 21 March 2026 (translated from German)

“The biggest danger is to cling too long to what was”

Britta Fünfstück, CEO · Schwäbische Post interview on PLUS2030, 21 March 2026 (translated from German)

“crisis resilience currently has no priority in healthcare”

Britta Fünfstück, CEO · Süddeutsche Zeitung Dossier article reprinted by HARTMANN, 2026 (translated from German)

“a strategically important step for the digitalisation and optimisation of our company”

Oliver Neubrand, CFO · On the SAP S/4HANA conversion, Annual Report 2025 (translated from German)

Where a supplier can help

Regulatory data and MDR compliance
Tied to the regulatory burden challenge: product data management, EUDAMED submission and recertification services for tens of thousands of products.
AI and process automation
Tied to the PLUS2030 efficiency goals and the SAP S/4HANA rollout: automation, analytics and AI use cases on the new ERP backbone.
Energy and freight cost reduction
Tied to the cost inflation challenge: energy procurement, efficiency and logistics optimisation for plants in Germany, France, Spain, the Czech Republic, Poland and Switzerland.
US market entry support
Tied to the US advanced wound care priority and the tariff challenge: distribution, market access and reimbursement services in the US outpatient market.
Production automation
Tied to the production capex and Asian price pressure: high-speed lines and automation that keep European plants competitive.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like HARTMANN GROUP?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about HARTMANN GROUP

What does HARTMANN do?

HARTMANN makes medical and care products, including MoliCare incontinence products, Zetuvit and Cosmopor wound dressings and Sterillium disinfectants, plus Kneipp personal care, for hospitals, care homes, pharmacies and home care.

What is HARTMANN's revenue?

FY2025 revenue was EUR 2,449.6 million with adjusted EBITDA of EUR 276.9 million. H1 2026 revenue was EUR 1,252.0 million.

How many employees does HARTMANN have?

HARTMANN employed 10,066 people at the end of 2025 and 9,881 at 30 June 2026.

What is HARTMANN's strategy?

The PLUS2030 strategy aims to grow faster than competitors in market share and margin and reach a number 1 or 2 position in Europe in each segment, supported by cost efficiency, innovation and AI.

Who leads HARTMANN?

Britta Fünfstück is CEO of PAUL HARTMANN AG, with Oliver Neubrand as CFO; Fritz-Jürgen Heckmann chairs the Supervisory Board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)